Skip to content

Clinical trials

Phase 1 Multiple Myeloma trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Myeloma Phase: Phase 1 Country / region: China Clear all

142 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20152
20162
20171
201811
201916
202011
202117
202217
202314
202415
202518
202617

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status56
Recruiting47
Completed14
Not yet recruiting13
Active, not recruiting6
Withdrawn2
Suspended2
Terminated2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Zhejiang University9
Institute of Hematology & Blood Diseases Hospital, China8
Shanghai Changzheng Hospital8
Hrain Biotechnology Co., Ltd.4
Peking Union Medical College Hospital4
The First Affiliated Hospital with Nanjing Medical University4
Chongqing Precision Biotech Co., Ltd3
Chunrui Li3
Peking University First Hospital3
Second Affiliated Hospital of Xi'an Jiaotong University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Myeloma142
Recurrence31
Lymphoma, Non-Hodgkin7
Leukemia, Plasma Cell6
Lymphoma, B-Cell5
Burkitt Lymphoma4
Lymphoma4
Hematologic Neoplasms3
Leukemia, Myeloid, Acute2
Neoplasms, Plasma Cell2

Trials

Showing 1 to 25 of 142. Each trial links to its page on Pharma Observatory.

42 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.